Keenova's Acthar and XIAFLEX lift guidance, but the quarter still ends in a $96M loss
Third-quarter net sales from continuing operations reached $550 million and full-year targets rose, yet a Percocet divestiture loss kept Keenova in the red.
The quarter in numbers
Keenova Therapeutics, formerly Mallinckrodt, reported net sales from continuing operations of $550 million for the quarter ended September 30, 2026. That is $133 million above the same period of 2025, which implies a prior-year base of about $417 million. Loss from continuing operations narrowed to $96 million from $242 million. Adjusted EBITDA from continuing operations was $233 million, or roughly 42% of net sales on our arithmetic.
The company did not give a prior-year Adjusted EBITDA figure in the release text provided, so the year-over-year trend in the non-GAAP measure cannot be read from it. The company also changed its Adjusted EBITDA definition in the second quarter of 2026 to add an adjustment for strategic initiative costs, and said it recast prior periods. Comparisons with earlier reports should account for that.
Subscribe to keep reading
$4.99 / month
- Every article, analysis and opinion piece on CompePharma and VigiEye
- One subscription for both sites, cancel any time
Already a subscriber? Enter your email below: we'll send you a sign-in link. No password needed.
Sources
- Keenova Therapeutics plc: quarterly results release (SEC filing) SEC EDGAR · 10 Nov 2026
Written by CompePharma's editorial system (AI-assisted, model claude-sonnet-5-5) strictly from the official material listed. Earnings analysis is based on the company's results release filed with the SEC, not on the earnings call. It can contain errors; check the sources. Not investment advice.
CorMedix Q3: Post-TDAPA DefenCath Reset Meets Heron Deal and a Suspended 2027 Outlook
Consolidated revenue of $54.5M beat the consensus the company cited, but DefenCath pricing, a $3.1M adjusted EBITDA and suspended 2027 guidance leave Heron and REZZAYO carrying the story.
Iambic's Q3: AI-platform deals double revenue, but the clinic drives the burn
Collaboration revenue rose to $11.4M and pro forma cash reached about $455M after the IPO, while R&D and G&A spending climbed as Iambic moves three oncology assets toward and into the clinic.
Alumis posts narrower Q3 loss as NDA nears, but a lupus miss narrows envudeucitinib's path
Lower R&D cut the quarterly net loss to $94.9M, with a psoriasis NDA still due in 4Q 2026 and cash guided into 4Q 2027, while the LUMUS Phase 2b missed in the overall population.